RxDoctor Payments Data

Parminder Sidhu, MD

Internal Medicine · Fountain Hills, AZNPI 1629379904

Payments from drug & device makers

$1,274in general payments, 2019–2025

Across 27 payments — averaging $47.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$602
  • Boston Scientific$138
  • Johnson & Johnson$112
  • Covidien LP$103
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$97
  • Exact Sciences$39
  • plus $183 from 7 others

What the payments were for

  • Food & beverage$1,274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,274 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$169,992
Medicare patients
435
Services billed
1,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$68,935
OzempicSemaglutide52$57,674
XareltoRivaroxaban24$33,691
JardianceEmpagliflozin31$33,456
TrulicityDulaglutide14$23,683
ProliaDenosumab12$21,477
FarxigaDapagliflozin Propanediol19$21,027
MounjaroTirzepatide11$18,189
SymbicortBudesonide/Formoterol Fumarate12$7,939
Advair HfaFluticasone Propion/Salmeterol20$7,026
Qvar RedihalerBeclomethasone Dipropionate11$4,287
Atorvastatin Calcium434$3,670
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$3,178
Levothyroxine Sodium330$2,820
Celecoxib63$2,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$68,93554 claims
Johnson & JohnsonXarelto$112$33,69124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Fountain Hills

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →